Department of Pharmacognosy and Biomaterials, Faculty of Pharmacy, Poznan University of Medical Sciences, 3 Rokietnicka St., 60-806 Poznan, Poland.
Department of Chemical Technology of Drugs, Poznan University of Medical Sciences, 3 Rokietnicka St., 60-806 Poznan, Poland.
Int J Mol Sci. 2024 Mar 25;25(7):3648. doi: 10.3390/ijms25073648.
In this study, binary amorphous solid dispersions (ASDs, fisetin-Eudragit) and ternary amorphous solid inclusions (ASIs, fisetin-Eudragit-HP-β-cyclodextrin) of fisetin (FIS) were prepared by the mechanochemical method without solvent. The amorphous nature of FIS in ASDs and ASIs was confirmed using XRPD (X-ray powder diffraction). DSC (Differential scanning calorimetry) confirmed full miscibility of multicomponent delivery systems. FT-IR (Fourier-transform infrared analysis) confirmed interactions that stabilize FIS's amorphous state and identified the functional groups involved. The study culminated in evaluating the impact of amorphization on water solubility and conducting in vitro antioxidant assays: 2,2-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)-ABTS, 2,2-diphenyl-1-picrylhydrazyl-DPPH, Cupric Reducing Antioxidant Capacity-CUPRAC, and Ferric Reducing Antioxidant Power-FRAP and in vitro neuroprotective assays: inhibition of acetylcholinesterase-AChE and butyrylcholinesterase-BChE. In addition, molecular docking allowed for the determination of possible bonds and interactions between FIS and the mentioned above enzymes. The best preparation turned out to be ASI_30_EPO (ASD fisetin-Eudragit containing 30% FIS in combination with HP-β-cyclodextrin), which showed an improvement in apparent solubility (126.5 ± 0.1 µg∙mL) and antioxidant properties (ABTS: IC = 10.25 µg∙mL, DPPH: IC = 27.69 µg∙mL, CUPRAC: IC = 9.52 µg∙mL, FRAP: IC = 8.56 µg∙mL) and neuroprotective properties (inhibition AChE: 39.91%, and BChE: 42.62%).
在这项研究中,通过无溶剂的机械化学方法制备了二聚无定形固体分散体(ASD,非瑟酮-Eudragit)和三聚无定形固体包合物(ASI,非瑟酮-Eudragit-HP-β-环糊精)。使用 X 射线粉末衍射(XRPD)确认了 ASD 和 ASI 中非瑟酮的无定形性质。差示扫描量热法(DSC)证实了多组分递药系统的完全混溶性。傅里叶变换红外分析(FT-IR)证实了稳定非瑟酮无定形态的相互作用,并确定了涉及的功能基团。该研究的最终目标是评估非晶化对水溶性的影响,并进行体外抗氧化测定:2,2-氮杂-双(3-乙基苯并噻唑啉-6-磺酸)-ABTS、2,2-二苯基-1-苦基肼基-DPPH、铜还原抗氧化能力-CUPRAC 和铁还原抗氧化能力-FRAP,以及体外神经保护测定:乙酰胆碱酯酶-AChE 和丁酰胆碱酯酶-BChE 的抑制作用。此外,分子对接允许确定非瑟酮与上述酶之间可能的键和相互作用。结果表明,最好的制剂是 ASI_30_EPO(ASD 非瑟酮-Eudragit 含有 30%的非瑟酮与 HP-β-环糊精结合),其表现出明显的溶解度提高(126.5 ± 0.1 µg·mL)和抗氧化性能(ABTS:IC = 10.25 µg·mL,DPPH:IC = 27.69 µg·mL,CUPRAC:IC = 9.52 µg·mL,FRAP:IC = 8.56 µg·mL)和神经保护性能(AChE 抑制率:39.91%,BChE 抑制率:42.62%)。